Carboplatin Single-cell Pharmacodynamics in Ovarian cancer
I am investigating the mechanisms of Carboplatin resistance in patients with High Grade Serous Ovarian Cancer (HGSOC). Around 80% of ovarian cancer patients have only a partial or temporary response to chemotherapy. To elucidate the causes of heterogeneity in resistant tumor cells, I use a range of single-cell techniques.
My project is part of the research fo the DNA Replication & Genome Protection group of Bart Westendorp and is financed by the Dutch Cancer Society (KWF). Our group resides in the Regenerative Medicine Center Utrecht (RMCU).